Characterization of disease-associated, cell-free nucleic acids (liquid biopsy) provides a powerful, minimally-invasive means for early disease detection, genotyping, and personalized therapy.
Introduction
In recent years, researchers have identified various enzymes from archaea and bacteria that can be programmed with nucleic acids to cleave complementary strands, among which CRISPR-Cas have attracted considerable attention as genome-editing tools [1] [2] [3] . In medical diagnostics, CRISPR-associated nucleases have been programmed to amplify reporter signals during nucleic acid detection [4] [5] [6] [7] and enrich rare alleles to enhance detection limits of oncogenic sequences [8] [9] [10] .
Despite spectacular progress, the utility of CRISPR-Cas in diagnostics is limited because it requires that the target contains a protospacer-adjacent motif (PAM) [8] [9] [10] , which is absent in many sequences of clinical interest.
Analogous to CRISPR-Cas, Argonaute (Ago) proteins 11 are nucleic acid-guided endonucleases.
In contrast to Cas nucleases, Ago nucleases do not require the presence of a PAM and are, therefore, more versatile than CRISPR-Cas. We found that under appropriate conditions, Ago from the thermophilic bacterium Thermus thermophilus (TtAgo) cleaves with high efficiency DNA and RNA complimentary to the DNA guide, but spares nucleic acids with a single nucleotide mismatch at and around the catalytic site with extraordinary sensitivity. Based on these findings, we established a new PAM-independent, rare allele enrichment assay ( Fig. 1) based on TtAgo termed NAVIGATER (Nucleic Acid enrichment Via DNA Guided Argonaute from Thermus thermophilus).
TtAgo uses a pair of short 5′-phosphorylated single-stranded DNA oligos as guides to selectively cleave complementary double-strand (ds) alleles [12] [13] [14] [15] while sparing alleles with a single nucleotide mismatch with guide. We optimize guide length, assay composition, and incubation temperature to enable NAVIGATER to increase rare allele fractions of KRAS, EGFR, and BRAF mutants in various samples. Furthermore, we demonstrate that NAVIGATER improves significantly the sensitivity of downstream detection schemes such as droplet digital PCR (ddPCR) 16 , Peptide Nucleic Acid-Mediated PCR (PNA-PCR) 17 , PNA-Loop Mediated Isothermal Amplification (LAMP) 18 , Xenonucleic Acid clamp PCR (XNA-PCR) 19 , and Sanger sequencing. As liquid biopsy (LB), especially monitoring of somatic mutations through cell-free DNA, becomes more common, methods such as NAVIGATER for enhancing sensitivity of non-invasive detection of critical diagnostic information will improve the clinical utility of such tests.
Results

Betaine, Mg 2+ , and dNTPs enhance TtAgo's cleavage efficiency of targeted nucleic acids
We envision applying NAVIGATER in combination with enzymatic amplification, in either a single-stage or a two-stage process, for rapid, inexpensive genotyping of rare mutant alleles (MAs).
An enzymatic amplification process of particular interest is LAMP 20 since it does not require temperature cycling and can be implemented with simple instrumentation in resource poor settings 20 . We tested TtAgo's activity in three modified variants of LAMP buffers and in a previously described custom cleaving Buffer S 15 (Table 1) .
We incubated TtAgo with either ssDNA or ssRNA fragments (100 nt) of the human KRAS gene and a 16 nt guide with a perfect match to the wild type (WT) KRAS, but with a single nucleotide mismatch at guide position 12 (g12) with KRAS-G12D. Cleavage products were subjected to gel electrophoresis (Supplementary Section 1) . We define the cleavage efficiency as Γ=I C /(I C +I UC ),
where I C and I UC are, respectively, band intensities of cleaved and uncleaved alleles. Comparing Γ in different buffers reveals that the cleavage efficiency in Buffer 3 is nearly 100% for both WT DNA ( Fig. 2a ) and WT RNA ( Fig. 2c) Fig. 1c ). Γ WT RNA increases as [Mg 2+ ] increases at both 70 o C and 80 o C ( Fig. 2c and Supplementary Fig. 3 ). Divalent cations, such as Mg 2+ are essential for endonucleolytic activity 14, 15, 21, 22 and stabilize the TtAgo-guide-target ternary complex 20 .
Betaine significantly increases Γ WT DNA ( Fig. 2b and Supplementary Figs. 1a) but increases Γ WT RNA to a lesser degree ( Fig. 2d ). Supplementing Buffer S with both Mg 2+ (6 mM) and betaine (0.8 M) increased the TtAgo cleavage efficiency from 60% to nearly 100% ( Supplementary Fig.   1a ) at 80 o C. This is consistent with betaine's ability to increase thermal stability of polymerase enzymes 23 and to dissolve secondary GC structure 24 during DNA amplification. Addition of 1.4 mM dNTPs increases Γ WT DNA to ~100% at 80 o C (Supplementary Fig. 1a ) similar to betaine's effect.
At 80 o C and in the absence of dNTPs, the Γ WT RNA peaks at [Mg 2+ ] ~10 mM ( Supplementary   Fig. 3a, left) . In contrast, in the presence of 1.4 mM dNTPs, Γ WT RNA increases as [Mg 2+ ] increases at both 80 o C ( Supplementary Fig. 3a, right) and 70 o C (Supplementary Figs. 3c and   3d ). To ascertain that the beneficial effects of dNTPs are not unique to KRAS, we also tested cleavage efficiency of EFGR target sequences ( Supplementary Fig. 5a ). In the absence of dNTPs, EGFR Γ WT RNA ~45% while in the presence of 1.4 mM dATP, dTTP or dCTP, Γ WT RNA ~100%. Surprisingly, addition of 1.4 mM dGTP does not affect cleavage efficiency. Among NTPs, only CTP increases Γ WT RNA (Supplementary Fig. 5b ). Although the molecular basis of this phenomenon remains elusive, it appears that the combination of sugar groups and nitrogenous bases of dNTPs stimulates TtAgo's activity.
TtAgo's activity increases as pH increases from 6.6 to 9.0 ( Supplementary Fig. 5c ). Among the buffers tested, Buffer 3 provides the best conditions for effective TtAgo cleavage of targeted WT alleles likely due to the presence of betaine, dNTPs, and 8 mM [Mg 2+ ]. Notably, TtAgo retains its specificity in the presence of the above additives with Γ MA <1%.
Single base pair-mismatch discrimination
To cleave WT alleles efficiently while sparing alleles with single nucleotide mutations, we designed guide DNAs (gDNAs) with a single base pair mismatch with MAs. A mismatch in the seed region of mouse Argonaute (AGO2) enhances the guide-allele dissociation rate 25 , reducing its cleaving efficiency. Little is known, however, on the effects of guide-allele mismatches on TtAgo's catalytic activity. Molecular dynamic simulations predict that a single DNA guide -mRNA mismatch affects enzyme conformation and reduces activity, but agreement with experiments is imperfect 26 .
In the absence of a reliable predictive tool, we analyze experimentally the effect on enzyme activity of a single mismatch type and mismatch position (MP) between guide and KRAS, EGFR, and BRAF sequences ( Fig. 3 and Supplementary Section 2). We use the notation MP-x to indicate that MA's aberrant nucleotide pairs with guide's x th base, counted from guide's 5' end. Although all guides are complementary to their targets, variations in MP affected targets' cleavage locations ( Fig. 3a) , cleavage products' lengths ( Fig. 3b) , and, unexpectedly, cleaving efficiency ( Fig. 3c) . We define discrimination efficiency (DE) as the difference between TtAgo-guide complex cleaving efficiency of WT and that of MA ( Fig. 3d and Supplementary Fig. 14) . Mismatches at and around the cleavage site (g10/g11), especially at MP7 and MP9-MP13 yielded the greatest discrimination (DE>80%) for most cases examined (Fig. 3e) . The optimal MP depends, however, on the allele's sequence. Cleavage of RNA was more sensitive to MP than cleavage of DNA.
Single mismatches at position g4-g11 nearly completely prevented RNA cleavage (Supplementary Figs. 6e (KRAS G12D) and 9 (EGFR L858R)). Our data suggests that guide's sequence differently affects the conformation of the ternary TtAgo-gDNA-DNA and TtAgo-gDNA-RNA complexes 21 .
Short DNA guides (15/16 nt) provide best discrimination between WT and MA
In vitro, TtAgo operates with ssDNA guides ranging in length from 7 to 36 nt 13 . Heterologouslyexpressed TtAgo is typically purified with DNA guides ranging in length from 13 to 25 nt 15 completely suppressed with a short 16 nt guide (Fig 4a-i) . We observe a similar behavior with guides with single mismatches at other positions (Supplemental Fig. 16 ) and with other MA sequences (Fig 4a-ii) . Apparently, TtAgo with shorter guides form a less stable complex with offtargets than longer guides thus preventing undesired cleavage.
In contrast to MA DNA, the increase in temperature did not increase undesired cleavage of MA
RNA (Figs. 4a-i, bottom and 4b-ii)
, likely due to differences in the effects of ssDNA and ssRNA on enzyme conformation. When operating with a short 16 nt guide, single MP12 mismatch, and LAMP Buffer 3, TtAgo efficiently cleaves both WT RNA and DNA targets while avoiding cleavage of MAs between 66 °C and 86 °C ( Fig. 4c) , providing the high specificity that is crucial for an enrichment assay.
TtAgo efficiently cleaves targeted dsDNA only at temperatures above the dsDNA's melting temperature Guide-free TtAgo can degrade dsDNA at low temperatures, and self-generate and selectively load functional DNA guides 27 . This is, however, a slow process that takes place only when target DNA is rich in AT (<17% GC) 15 , suggesting that TtAgo lacks helicase activity and depends on dsDNA thermal breathing to enable chopping 11, 15, 28 . Furthermore, since our assay is rich in gDNA that forms a tight complex with TtAgo, TtAgo's direct interactions with dsDNA are suppressed.
TtAgo's ability to operate at high temperatures provides NAVIGATER with a clear advantage since dsDNA unwinds as the incubation temperature increases.
Here, we investigate TtAgo's cleavage efficiency of dsKRAS WT and MA as functions of 
Excess gDNA concentration is necessary to avoid off-target cleavage
At TtAgo:S-guide:AS-guide ratio of 1: 0.2: 0.2, non-specific, undesired cleavage of dsMA occurs ( Fig. 5b) . This off-target cleaving becomes more pronounced as the incubation time increases ( Fig. 5b) and can potentially be attributed to TtAgo's self-production of guides from dsDNA (chopping) 27 . Since gDNA forms a tight complex with TtAgo, excess gDNA reduces undesired chopping. When guide concentrations exceed TtAgo concentration, no apparent offtarget cleavage takes place (Figs. 5c, 5d and Supplementary Fig. 17 ). To avoid off-target cleaving, it is necessary to saturate TtAgo with guides and to limit incubation time. Indeed, at TtAgo:S-guide:AS-guide ratio of 1: 10: 10, NAVIGATER efficiently cleaves double strand WT KRAS, BRAF and EGFR while sparing point mutations KRAS G12D ( Fig. 5) , BRAF V600E, and EGFR L858R ( Supplementary Fig. 18 ), and EGFR deletion mutations in exon 19 ( Supplementary Fig. 19 ).
NAVIGATER improves the sensitivity of downstream rare allele detection
In recent years, there has been a rapidly increasing interest in applying LB to detect cell-free circulating nucleic acids associated with somatic mutations for, among other things, cancer diagnostics, tumor genotyping, and monitoring susceptibility to targeted therapies. LB is attractive since it is minimally invasive and relatively inexpensive. Detection of MAs is, however, challenging due to their very low concentrations in LB samples among the background of highly abundant WT alleles that differ from MAs by as little as a single nucleotide. To improve detection sensitivity and specificity of detecting rare alleles that contain valuable diagnostic and therapeutic clues, it is necessary to remove and/or suppress the amplification of WT alleles [30] [31] [32] . NAVIGATER meets this challenge by selectively and controllably degrading WT alleles in the sample to increase the fraction of MAs. We demonstrate here that single-plex and multiplex NAVIGATER increases sensitivity of downstream mutation detection methods such as gel electrophoresis, ddPCR 16 , PNA-PCR 17 , PNA-LAMP 18 , XNA-PCR 19 and Sanger sequencing. Moreover, to demonstrate NAVIGATER's potential clinical utility, we enriched blood samples from pancreatic cancer patients, which have been previously analyzed with standard ddPCR protocol ( Table 2) . These samples were pre-amplified by PCR to increase WT and MA KRAS total content before enrichment. Fig. 20) : We subjected enrichment assay products of pancreatic cancer patients ( Table 2 ) to gel eIectrophoresis. In the absence of enrichment (control), the bands at 80 bp (KRAS) on the electropherogram are dark. After 40 minutes of TtAgo enrichment, these bands faded, indicating a reduction of KRAS WT alleles. After 2 hours enrichment, all the bands at 80 bp, except that of patient P6, have essentially disappeared, suggesting that most WT alleles have been cleaved. The presence of an 80 bp band in the P6 lane is attributed to the relatively high (20%) MA fraction that is not susceptible to cleaving. We also PCR amplified products from a 2-hour NAVIGATER treatment, and subjected the amplicons to a second NAVIGATER (2h). The columns P3, P4, and P6 feature darker bands than P1, P2 and P5, indicating the presence of MAs in samples P3, P4, and P6 (Supplementary Fig. 20 ) and demonstrating that NAVIGATER renders observable otherwise undetectable MAs.
Gel electrophoresis (Supplementary
Droplet Digital PCR (ddPCR) ( Supplementary Fig. 21 ): To quantify our enrichment assay products, we subjected them to ddPCR. The detection limit of ddPCR is controlled by the number of amplifiable nucleic acids in the sample, which must be a small fraction of the number of ddPCR droplets. The large number of WT alleles in the sample limits the number of pre-ddPCR amplification cycles that can be carried out to increase rare alleles' concentration. Since NAVIGATER drastically reduces the number of WT alleles in the sample, it enables one to increase the number of pre-amplification cycles, increasing the number of MAs and ddPCR sensitivity. When operating with a mixture of WT and MA, NAVIGATER products include: residual uncleaved WT (N WT ), MA (N MA ), and WT-MA hybrids (N H ). Hybrid alleles form during rehybridization of an ssWT with an ssMA. The MA fraction is f MA =(N MA +½N H )/(N WT +N MA +N H ).
We carried out ddPCR on un-enriched (control, NAVIGATER without TtAgo), once-enriched, and twice-enriched samples (Supplementary Fig. 21b ), increasing f MA significantly (Fig. 6a) . For example, f MA increased from 0.5% in the un-enriched P5 (G12D) sample to ~30% in the twiceenriched sample. This represents a ~60 fold increase in the fraction of droplets (f MA ) containing MA (Fig. 6b) . The same assay also enriched G12R, increasing f MA from 3% to ~66% in sample P3 and G12V, increasing f MA from 5% to ~68% in sample P4 (Fig. 6b) .
PNA-PCR: PNA-PCR engages a sequence-specific PNA blocker that binds to WT alleles, suppressing WT amplification and providing a limit of detection of f MA ~1% 17 . To demonstrate NAVIGATER's utility, we compared the performance of PNA-PCR when processing pancreatic cancer patient samples ( Table 2 ) before and after NAVIGATER (Figs. 6c, 6d, and 6e) . Before enrichment, PNA-PCR real-time amplification curves in the order of appearance are P6, P4, and P3, as expected ( Table 2) . Samples P1 (f MA =0), P2 (f MA =0), and P5 (f MA =0.5%) nearly overlap, consistent with a detection limit of ~1% 17 . Enrichment (Fig. 6d ) significantly increases the threshold times of samples P1 and P2, revealing the presence of MAs in sample P5. PNA-PCR combined with NAVIGATER provides the linear relationship T 1/2 = 22.9-5 log(f MA ) between threshold time (the time it takes the amplification curve to reach half its saturation value) and allele concentration ( Fig. 6e) , allowing one to estimate MA concentration. The data suggests that NAVIGATER can improve PCR-PNA limit of detection to below 0.1%. PNA-LAMP: Genotyping with PNA blocking oligos can be combined with the isothermal amplification LAMP 18 . To demonstrate the feasibility of genotyping at the point of care and resource-poor settings, we use a minimally-instrumented, electricity-free Smart-Connected Cup (SCC) 20 with smartphone and bioluminescent dye-based detection to incubate PNA-LAMP and detect reaction products. To demonstrate that we can also detect RNA alleles, we used simulated samples comprised of mixtures of WT KRAS mRNA and KRAS-G12D mRNA. In the absence of pre-enrichment, SSC is unable to detect the presence of 0.1% KRAS-G12D mRNA whereas with pre-enrichment 0.1% KRAS-G12D mRNA is readily detectable (Fig. 6f) .
Sanger Sequencing: In the absence of enrichment, Sanger sequencers detect >5% MA fraction 33 .
The Sanger sequencer failed to detect the presence of f MA~3 % and 0.5% KRAS-G12D mRNA in our un-enriched samples, but readily detected these MAs following NAVIGATER enrichment (Fig.   6g ). Section 5) : XNA-PCR 19 is a clamped assay that suppresses amplification of WT alleles, enabling detection of MAs down to 0.1% fraction. We used multiplexed NAVIGATER with 3 different guides to enrich samples of 60 ng cfDNA that included WT and various fractions of KRAS G12D, EGFR ΔE746 -A750, and EGFR L858R. Without NAVIGATER, XNA-PCR was able to detect down to 0.1% KRAS G12D (Fig. 6h) , 0.1% EGFR ΔE746 -A750 ( Supplementary Fig. 23e) , and 1% EGFR L858R (Supplementary Fig. 23c ). With NAVIGATER pre-treatment, XNA-PCR sensitivity increased by over 10 fold to 0.01% KRAS G12D (Fig. 6i) , 0.01% EGFR ΔE746 -A750 (Supplementary Fig. 23f) , and 0.1% EGFR L858R ( Supplementary   Fig. 23d ). Here, in addition to significantly improving the sensitivity of XNA-PCR, we also demonstrate that NAVIGATER can operate as a multiplexed assay, enriching for multiple MAs.
XNA-PCR (Supplementary
Discussion
LB is a simple, minimally invasive, rapidly developing diagnostic method to analyze cell-free nucleic acid fragments in body fluids and obtain critical diagnostic information on patient health and disease status. Currently, LB can help personalize and monitor treatment for patients with advanced cancer, but the sensitivity of available tests is not yet sufficient for patients with early stage disease 32 or for cancer screening. Detection of alleles that contain critical clinical information is challenging since they are present at very low concentrations among abundant background of nucleic acids that differ from alleles of interest by as little as a single nucleotide.
Here, we report on a novel enrichment method (NAVIGATER) for rare alleles that uses TtAgo.
TtAgo is programmed with short ssDNA guides to specifically cleave guide-complementary alleles and stringently discriminate against off-targets with a single nucleotide precision. Sequence mismatches between guide and off-targets reduce hybridization affinity and cleavage activity by sterically hindering the formation of a cleavage-compatible state 13, 14 . We observe that TtAgo's activity and discrimination efficiency depend sensitively on the (i) position of the mismatched pair along the guide, (ii) buffer composition, (iii) guide concentration, (iv) guide length, (v) incubation temperature and time, and (vi) target sequence. TtAgo appears to discriminate best between target and off-target in the presence of a mismatch at or around the cleavage site located between guide We demonstrate NAVIGATER's ability to enrich the fraction of cancer biomarkers such as KRAS, BRAF, and EGFR mutants in various samples. For example, NAVIGATER increased KRAS G12D fraction from 0.5% to 30% (60 fold) in a blood sample from a pancreatic cancer patient. The presence of 0.5% KRAS G12D could not be detected with Sanger sequencer or PNA-PCR.
However after NAVIGATER pre-processing, both the Sanger sequencer and PNA-PCR readily identified the presence of KRAS G12D. Additionally, NAVIGATER combined with PNA-LAMP detects low fraction (0.1%) mutant RNA alleles and NAVIGATER combined with PNA-LAMP enables genotyping at the point of care and in resource-poor settings. NAVIGATER improves the detection limit of XNA-PCR by more than 10 fold, enabling detection of rare alleles with frequencies as low as 0.01%. NAVIGATER differs from previously reported rare allele enrichment methods [8] [9] [10] [34] [35] [36] [37] [38] in several important ways ( Table 3) . First, NAVIGATER is versatile. In contrast to CRISPR-Cas9 8-10 and restriction enzymes 34 , TtAgo does not require a PAM motif or a specific recognition site. A gDNA can be designed to direct TtAgo to cleave any desired target. Second, TtAgo is a multi-turnover enzyme 15 ; a single TtAgo-guide complex can cleave multiple targets. In contrast, CRISPR-Cas9 is a single turnover nuclease 39 (Supplementary Fig. 24 ).
Purified TtAgo protein was diluted in a size exclusion buffer to a final concentration of 5 µM.
Aliquots were flash frozen in liquid nitrogen and stored at -80 o C. TtAgo, DNA guides, and ssDNA or ssRNA targets were mixed with TtAgo and guides at the ratios indicated in the buffers listed in Table 1 and incubated at the indicated temperatures.
TtAgo -based cleavage assays
Reactions were terminated by adding 1 µL proteinase K (Qiagen, Cat. No. 19131) solution, followed by 15 min incubation at 56°C. Samples were then mixed with 2X loading buffer (95% (de-ionized) formamide, 5mM EDTA, 0.025% SDS, 0.025% bromophenol blue and 0.025% xylene cyanol) and heated for 10 min at 95°C before the samples were resolved on 15% denaturing polyacrylamide gels (7M Urea). Gels were stained with SYBR gold Nucleic Acid Gel Stain (Invitrogen) and nucleic acids were visualized using a BioRad Gel Doc XR+ imaging system. For dsDNA cleavage, TtAgo and guides were pre-incubated in LAMP Buffer 3 ( Table 1) at 75 °C for 20 min.
Cell-free DNA (cfDNA) and RNA Samples
Patient cfDNA samples. All six blood samples ( Table 2) were obtained from patients with metastatic pancreatic cancer who had provided informed consent under the IRB-approved protocol (UPCC 02215, IRB# 822028). cfDNA was extracted with QIAamp ® Circulating Nucleic Acid kit (Qiagen, Valencia, CA, USA). Subsequently, the extracted cfDNA was qualified and quantified with multiplex ddPCR (Raindance).
RNA samples. Total RNA was extracted with RNeasy ® mini kit (Qiagen, Valencia, CA, USA) per manufacturer's protocol from Human cancer cell lines U87-MG (WT KRAS mRNA) and ASPC1 (KRAS G12D mRNA) and quantified with ddPCR.
cfDNA pre-amplification was carried out in 50-µL reaction volumes using 20 ng of cfDNA, 1 × Q5 Hot Start High-Fidelity Master Mix (New England Biolabs, Ipswich, MA), and 100 nM each of forward and reverse KRAS 80 bp-PCR primers (Supplementary Table 1) . Reaction mixes without DNA were included as no-template (negative) controls (NTCs). Nucleic acids were preamplified with a BioRad Thermal Cycler (BioRad, Model CFD3240) with a temperature profile of 98°C for 3 minutes, followed by 30 cycles of amplification (98°C for 10 seconds, 63°C for 3 minutes, and 72°C for 30 seconds), and a final 72 °C extension for 2 minutes.
mRNA pre-amplification was performed in 50-µL reactions using 30 ng of total RNA, 1 × Q5 Hot Start High-Fidelity Master Mix (New England Biolabs, Ipswich, MA), 100 nM each of forward and reverse KRAS 295 bp-PCR primers (Supplementary Table 1) , and 1 µL reverse transcriptase (Invitrogen, Carlsbad, CA). The reaction mix was incubated at 55 °C for 30 minutes and 98°C for 3 minutes, followed by 30 cycles of amplification (93°C for 15 seconds, 62°C for 30 seconds, and 72°C for 30 seconds), and a final 72°C extension for 4 minutes.
Mutation enrichment (NAVIGATER)
The same setup as for synthetic dsDNA cleavage was used for cf-ctDNA and mutant mRNA enrichment. TtAgo, S-guide, and AS-guide were mixed in 1: 10: 10 ratio (1.25 µM TtAgo, 12.5 µM S-guide, 12.5 µM AS-guide) in the Buffer 3 and pre-incubated at 75 °C for 20 min. Samples consisted of 2 µL preamplified PCR or RT-PCR products were added after pre-incubation of TtAgo and guides. The reaction mixes were incubated at 83°C for 1 hour. The enriched products were diluted 10 4 fold before downstream mutation analysis or second-round enrichment. For second-round enrichment, the protocol outlined above was repeated.
NAVIGATER combined with downstream mutation detection methods
Droplet digital PCR (ddPCR). ddPCR was carried out with the RainDrop Digital PCR system (RainDance Technologies, Inc.) to verify mutation abundance before and after TtAgo enrichment. 2 µL of the 10 4 -fold diluted, TtAgo-treated sample was added to each 30-µL dPCR. dPCRs contained 1× TaqMan Genotyping Master Mix (Life Technologies), 400 nM KRAS 80bp-PCR primers, 100 nM KRAS wild-type target probe, 100 nM KRAS mutant target probe (Supplementary Table 1) , and 1× droplet stabilizer (RainDance Technologies, Inc.). Emulsions of each reaction were prepared on the RainDrop Source instrument (RainDance Technologies, Inc.) to produce 2 to 7 million, 5-pLvolume droplets per 25-µL reaction volume. Thereafter, the emulsions were placed in a thermal cycler to amplify the target and generate signal. The temperature profile for amplification consisted of an activation step at 95°C for 10 minutes, followed by 45 cycles of amplification [95°C for 15 seconds and 60°C for 45 seconds]. Reaction products were kept at 4°C before placing them on the Supplementary Table 1 ). The prepared reaction mixtures were injected into reaction chambers of our custom made multifunctional chip 42, 43 . The inlet and outlet ports were then sealed with transparent tape (3M, Scotch brand cellophane tape, St. Paul, MN) and the chip was placed in our portable Smart-Connected Cup and processed according to previously described protocol 20 .
Multiplexed NAVIGATER and XNA-PCR. hour. The products with and without TtAgo treatment were resolved on 15% denaturing polyacrylamide gels (7M Urea). The products were diluted 10 7 fold before downstream mutation analysis.
Single-plex and
XNA-PCR: NAVIGATER products were tested by mutation detection method XNA-PCR 19 (DiaCarta, Inc.). XNA-PCR was carried out for individual mutants in 10-µL reaction volumes, containing 3 µL of the 10 7 -fold diluted NAVIGATER products, 1 × PCR Master Mix, 1 µL of PCR primer/probe mix, and 1 µL of XNA clamp. Reactions were amplified with a BioRad Thermal Cycler (BioRad, Model CFX96) with a temperature profile of 95 °C for 5 minutes, followed by 45 cycles of amplification (95 °C for 20 seconds, 70 °C for 40 seconds, 60 °C for 30 seconds, and 72 °C for 30 seconds). 
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